<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03530696</url>
  </required_header>
  <id_info>
    <org_study_id>29747</org_study_id>
    <secondary_id>T-DM1</secondary_id>
    <secondary_id>Palbo T-DM1</secondary_id>
    <nct_id>NCT03530696</nct_id>
  </id_info>
  <brief_title>T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer</brief_title>
  <acronym>T-DM1</acronym>
  <official_title>A Single Arm Phase II Study to Evaluate Efficacy of T-DM1 With Palbociclib in the Treatment of Patients With Metastatic HER2 Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized phase II study to evaluate if the combination of T-DM1 with palbociclib&#xD;
      improves progression-free survival compared to single agent T-DM1in patients with metastatic&#xD;
      HER2 positive breast cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, phase II study of T-DM1 with or without palbociclib in&#xD;
      the treatment of patients with metastatic HER2-positive breast cancer. Patients will be&#xD;
      randomized 1:1 to T-DM1 with or without palbociclib.&#xD;
&#xD;
      Hypotheses: Combination of T-DM1 with palbociclib improves progression free survival compared&#xD;
      to single agent T-DM1&#xD;
&#xD;
      Primary objective: Compare progression free survival of the combination arm (T-DM1 with&#xD;
      palbociclib) to single agent T-DM1&#xD;
&#xD;
      Secondary objectives i) Compare response rates between both treatment arms ii) Compare&#xD;
      overall survival between both treatment arms&#xD;
&#xD;
      Correlative objectives i) Investigate predictive biomarkers of response in blood and archived&#xD;
      tumor tissue ii) Investigate mechanisms of resistance for palbociclib in blood and tumor&#xD;
      tissue&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare progression-free survival</measure>
    <time_frame>4 years</time_frame>
    <description>Compare progression-free survival of the combination arm (T-DM1 with palbociclib) to single agent T-DM1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare response rates</measure>
    <time_frame>4 years</time_frame>
    <description>Compare response rates between both treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare overall survival</measure>
    <time_frame>4 years</time_frame>
    <description>Compare overall survival between both treatment arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Breast Cancer Stage</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <condition>HER2 Positive Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>T-DM1 with palbociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DM1 is given IV every 21 days Palbociclib is administered days 5-18</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T-DM1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>T-DM1 is given IV every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Compare progression free survival of the combination arm (T-DM1 with palbociclib) to single agent T-DM1</description>
    <arm_group_label>T-DM1 with palbociclib</arm_group_label>
    <other_name>Ibrance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T-DM1</intervention_name>
    <description>Compare progression free survival of the combination arm (T-DM1 with palbociclib) to single agent T-DM1</description>
    <arm_group_label>T-DM1</arm_group_label>
    <arm_group_label>T-DM1 with palbociclib</arm_group_label>
    <other_name>Kadcyla</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be informed of the investigational nature of the study and all pertinent aspects of&#xD;
             the trial&#xD;
&#xD;
          2. Sign and provide written consent in accordance with institutional and federal&#xD;
             guidelines.&#xD;
&#xD;
          3. ECOG Performance status of 0-2&#xD;
&#xD;
          4. Recurrent or metastatic HER2-positive breast cancer (HER2 positive is defined per&#xD;
             ASCO-CAP guidelines)&#xD;
&#xD;
          5. Adequate cardiac reserve (EF≥50%)&#xD;
&#xD;
          6. Serum creatinine ≤ 1.5 x institutional upper limit of normal (IULN), bilirubin ≤ 2.0,&#xD;
             and an SGOT/SGPT/alkaline phosphatase ≤ 2.0 x IULN&#xD;
&#xD;
          7. Adequate bone marrow function (ANC ≥1000, Platelets ≥100,000/ml, Hemoglobin ≥10gm/dL)&#xD;
&#xD;
          8. Be willing and able to comply with scheduled visits, treatment plan, laboratory tests&#xD;
             and other trial procedures&#xD;
&#xD;
          9. Been treated with pertuzumab previously (neoadjuvant or metastatic setting). Patients&#xD;
             who weren't able to tolerate pertuzumab due to side effects can be eligible for study&#xD;
             upon discussion with the study PI&#xD;
&#xD;
         10. No more than 2 lines of therapy in the metastatic disease setting&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HER2 negative tumors&#xD;
&#xD;
          2. Prior treatment with T-DM1&#xD;
&#xD;
          3. Prior treatment with CDK 4/6 inhibitors&#xD;
&#xD;
          4. Known active CNS metastases or carcinomatous meningitis. Patients with stable CNS&#xD;
             metastases including brain metastases who have completed a course of radiotherapy are&#xD;
             eligible for the study provided they are clinically stable. However, oral&#xD;
             corticosteroids for control of CNS symptoms are not allowed on study&#xD;
&#xD;
          5. Known documented or suspected hypersensitivity to the components of the study drug(s)&#xD;
             or analogs.&#xD;
&#xD;
          6. Uncontrolled systemic illness, including but not limited to ongoing or active&#xD;
             infection&#xD;
&#xD;
          7. Symptomatic congestive heart failure, unstable angina pectoris, stroke or myocardial&#xD;
             infarction within 3 months&#xD;
&#xD;
          8. Be pregnant or breast feeding. Female subjects must be surgically sterile or be&#xD;
             postmenopausal, or must agree to use effective contraception during the period of&#xD;
             therapy. All female subjects with reproductive potential must have a negative&#xD;
             pregnancy test (serum or urine) prior to enrollment and must agree to use effective&#xD;
             contraception during the period of therapy&#xD;
&#xD;
          9. Concurrent hormonal or other anti-neoplastic therapy is not allowed. Patients can&#xD;
             receive supportive therapy like bone-directed therapy including bisphosphonates or&#xD;
             denosumab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavani Chalasani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Arizona Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Niyuri Fleming</last_name>
    <phone>520-694-9079</phone>
    <email>nfleming@uacc.arizona.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Selegue, BA, BSN, RN</last_name>
      <phone>520-626-0301</phone>
      <email>aselegue@email.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Pavani Chalasani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedar-Sinai</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parisa Mirzadehgan</last_name>
      <email>Parisa.Mirzadehgan@cshs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyrie Dailey</last_name>
      <phone>720-848-9456</phone>
      <email>KYRIE.DAILEY@UCDENVER.EDU</email>
    </contact>
    <investigator>
      <last_name>Peter Kabos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Hofstatter, MD</last_name>
      <email>erin.hofstatter@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Erin Hofstatter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vered Stearns, MD</last_name>
      <phone>410-955-8964</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mosaic Life Care</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>65406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Hughes</last_name>
      <phone>816-271-7654</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursa Brown-Glaberman, MD</last_name>
      <phone>505-272-4946</phone>
    </contact>
    <investigator>
      <last_name>Ursa Brown-Glaberman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>800-767-9355</phone>
      <email>ASKRoswell@Roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Mateusz Opyrchal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Tole</last_name>
      <phone>984-974-8658</phone>
      <email>shannon_tole@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alycia Gatta</last_name>
      <phone>866-223-8100</phone>
      <email>TaussigResearch@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette Phillips</last_name>
      <phone>971-262-9041</phone>
      <email>philljea@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>JPS Health Network</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Diaz, MHA, CCRC</last_name>
      <phone>817-702-2349</phone>
      <email>ADiaz02@jpshealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hank Kaplan</last_name>
      <email>Hank.Kaplan@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Hank Kaplan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Specht, MD</last_name>
      <phone>206-606-6329</phone>
      <email>jspecht@uw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>UW Cancer Connect</last_name>
      <phone>608-262-5223</phone>
    </contact>
    <contact_backup>
      <phone>800-622-8922</phone>
    </contact_backup>
    <investigator>
      <last_name>Kari Wisinski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>May 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2018</study_first_posted>
  <last_update_submitted>September 4, 2021</last_update_submitted>
  <last_update_submitted_qc>September 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>HER2-positive</keyword>
  <keyword>T-DM1</keyword>
  <keyword>HER2-positive Breast Cancer</keyword>
  <keyword>Recurrent Breast Cancer</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

